GlassScriptPhysician profile
Michelle A Loubert
NPI 1245688514
$4,843.54
in general payments reported to CMS, 2019-2025
40 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $477 · 2021: $981 · 2022: $1,147 · 2023: $1,024 · 2024: $401 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.06 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.01 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $389.21 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $363.52 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $278.23 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $258.71 | 2020-2024 | Rexulti |
| Pfizer INC. | $253.60 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $225.46 | 2020-2025 | Ingrezza |
| Lilly USA, LLC | $218.30 | 2020-2025 | Mounjaro, Emgality, Reyvow |
| Glaxosmithkline, LLC. | $202.67 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $189.46 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.30 | 2020-2023 | |
| Novo Nordisk INC | $168.05 | 2020-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.48 | 2020-2022 | |
| Exact Sciences Corporation | $154.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $154.02 | 2020-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Loubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.